BioPass Pharma
Targeting Drugs and Molecules into the Brain
Company Overview
Snapshot
Founded in October 2021 by Elka Touitou, Tal Ben Yehuda, Shlomi Zandberg, and Hiba Natsheh, BioPass Pharma operates with 1-10 employees. The company has secured exclusive rights for its patented novel technology from the Hebrew University of Jerusalem, focusing on drug delivery to the brain.
Business overview
BioPass Pharma is a Health Tech & Life Sciences company developing a novel formulation for treating brain and Central Nervous System (CNS) diseases. Its core technology is designed to deliver molecules directly into the brain by bypassing the blood-brain barrier (BBB), utilizing a patented approach. The company's product offerings include a Targeted Carrier Formulation, a nasal drug delivery carrier, and Phospholipid Magnesome, all aimed at providing a non-invasive, painless, and easily administered treatment with short onset, avoiding gastrointestinal and hepatic presystemic metabolism. BioPass Pharma operates in the Pharma & Medical Biotechnology sector, specifically in Drug Delivery, and targets the global market, serving patients within the healthcare and life sciences industries.
Log in to access full profile ›Company Intelligence Q&A
- When was BioPass Pharma founded and by whom?
- BioPass Pharma was founded in October 2021 by Elka Touitou, Tal Ben Yehuda, Shlomi Zandberg, and Hiba Natsheh.
- What is BioPass Pharma's primary focus in drug development?
- BioPass Pharma focuses on developing a revolutionary formulation for the treatment of brain or CNS diseases by delivering molecules directly into the brain, bypassing the blood-brain barrier (BBB).
- What is the key technology behind BioPass Pharma's drug delivery system?
- BioPass Pharma's key technology involves a patented novel formulation designed for nasal drug delivery, offering a non-invasive and rapid-onset treatment method.
- From which institution did BioPass Pharma secure rights for its technology?
- BioPass Pharma secured exclusive rights for its patented novel technology from the Hebrew University of Jerusalem.
- What are the advantages of BioPass Pharma's nasal formulation?
- The company's novel nasal formulation offers short onset, is non-invasive, painless, and easily administered, while also avoiding gastrointestinal and hepatic presystemic metabolism.